A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- Registration Number
- NCT03481998
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Brief Summary
This is a phase IB/II clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole or Fulvestrant. Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 104
-
Has the pathologically-confirmed diagnosis of locally recurrent or metastatic, hormone-receptor positive, HER2 negative Breast Cancer.
-
Age: 18 - 75 years old, postmenopausal women.prepostmenopausal women, but should receive Ovary castration.
Inclusion Criteria
-
Cohort 1 and Cohort 2 :No prior systemic anti-cancer therapy for advanced HR+ disease.
Cohort 3 and Cohort 4 : Patients must satisfy the following criteria for prior therapy:
-
a) Progressed after 2 years during treatment of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre- or perimenopausal.
b)Progressed within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre- or perimenopausal.
c) Progressed while 6 month after the end of prior aromatase inhibitor therapy for advanced/metastatic breast cancer if postmenopausal, or prior endocrine treatment for advanced/metastatic breast cancer if pre- or perimenopausal.
-
One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy.
-
Eastern Cooperative Oncology Group [ECOG] 0-1 Measurable disease as per Response Evaluation Criterion in Solid Tumors[RECIST] 1.1
-
Adequate organ and marrow function
Exclusion Criteria
- Confirmed diagnosis of HER2 positive disease
- Patients who received any endocrine therapy as neo/adjuvant therapy for breast cancer are eligible. If the neo/adjuvant therapy of any endocrine therapy , the disease-free interval must be greater than 12 months from the completion of treatment until study entry.
- Patients who received prior treatment with any CDK4/6 inhibitor, everolimus,fulvestant.
- Clinically significant cardiovascular and cerebrovascular diseases,including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure (New York heart association (NYHA) class > 2), or ventricular arrhythmia which need medical intervention.
- Has known active central nervous system metastases.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Cohort 1 (Part 1) SHR6390 Participants receive SHR6390 (at protocol defined dose levels) in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously). Cohort 2 (Part 1) SHR6390 SHR6390 (TBD), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously). SHR6390 + Letrozole or anastrozole (Part 2) SHR6390 SHR6390 (RP2D, recommended Phase 2 dose), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously). SHR6390 + Letrozole or anastrozole (Part 2) Letrozole or anastrozole or Fulvestrant SHR6390 (RP2D, recommended Phase 2 dose), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously). SHR6390 + Fulvestrant Cohort 3 (Part 1) SHR6390 SHR6390 (at protocol defined dose levels), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily SHR6390 + Fulvestrant Cohort 3 (Part 1) Letrozole or anastrozole or Fulvestrant SHR6390 (at protocol defined dose levels), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily SHR6390 + Fulvestrant Cohort 4 (Part 1) SHR6390 SHR6390 (TBD), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily Cohort 1 (Part 1) Letrozole or anastrozole or Fulvestrant Participants receive SHR6390 (at protocol defined dose levels) in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously). Cohort 2 (Part 1) Letrozole or anastrozole or Fulvestrant SHR6390 (TBD), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously). SHR6390 + Fulvestrant Cohort 4 (Part 1) Letrozole or anastrozole or Fulvestrant SHR6390 (TBD), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily
- Primary Outcome Measures
Name Time Method Number of Participants With adverse events (AEs) and serious adverse events (SAEs) at Phase 1 Up to 4 weeks Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03.
Up to 24 months.
- Secondary Outcome Measures
Name Time Method Area under the plasma concentration versus time curve (AUC) of SHR6390 Up to 4 weeks The time of SHR6390 to reach the maximum concentration (Tmax) Up to 4 weeks Progression-free Survival (PFS) per RECIST 1.1 Up to approximately 24 months. PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first.
Peak Plasma Concentration (Cmax) of SHR6390 Up to 4 weeks Half-time (t1/2) of SHR6390 Up to 4 weeks Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Up to approximately 24 months. ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ¡Ý30% decrease in the sum of diameters of target lesions) per RECIST 1.1.
Disease Control Rate (DCR) per RECIST 1.1 Up to approximately 24 months. DCR is defined as the percentage of participants in the analysis population who have a CR, PR or SD per RECIST 1.1.
Number of Participants With adverse events (AEs) and serious adverse events (SAEs) Up to approximately 24 months. Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03.
Trial Locations
- Locations (4)
Ha'erbin Tumor Hospital
🇨🇳Ha'erbin, Heilongjiang, China
Henan Cancer Hospital
🇨🇳Zhengzhou, Henan, China
Sir Run Run Shaw Hospital of Zhejiang University
🇨🇳Hangzhou, Zhejiang, China
Cancer Hospital, Chinese Academy of Medical Sciences
🇨🇳Beijing, China